Expression of circulating miR-486 and miR-150 in patients with acute myocardial infarction

BMC Cardiovascular Disorders

Li Li¹  Li Huang¹  Guoyu Duan¹  Hui Pei¹  Chao Lan¹  Rui Zhang¹ 

[1] Department of emergency, The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe Road, Zhengzhou 450052, Henan, China

关键词: Biomarker;    MicroRNAs;    Acute myocardial infarction;   

Others  :  1216156
DOI  :  10.1186/s12872-015-0042-0

 received in 2015-02-28, accepted in 2015-06-01,  发布年份 2015

【 摘 要 】

Background

With its high morbidity and mortality, acute myocardial infarction (AMI) places a major burden on society and on individual patients. Correct, early correct diagnosis is crucial to the management of AMI.

Methods

In this study, the expression of circulating miR-486 and miR-150 was investigated in AMI patients and the two miRNAs were evaluated as potential biomarkers for AMI. Plasma samples from 110 patients with AMI (65 patients with ST-segment elevation myocardial infarction (STEMI) and 45 patients with non-ST-segment elevation myocardial infarction (NSTEMI)) and 110 healthy adults were collected. Circulating levels of miR-486 and miR-150 were detected using quantitative real-time PCR in plasma samples.

Results

Results showed that the levels of miR-486 and miR-150 were significantly higher in AMI patients than in healthy controls. Receiver operating characteristic (ROC) curve analyses indicated that the two plasma miRNAs were of significant diagnostic value for AMI, especially NSTEMI. The combined ROC analysis revealed an AUC value of 0.771 in discriminating AMI patients from healthy controls and an AUC value of 0.845 in discriminating NSTEMI patients from healthy controls.

Conclusion

Results indicated that the levels of circulating miR-486 and miR-150 are associated with AMI. They may be novel and powerful biomarkers for AMI, especially for NSTEMI.

【 授权许可】

   
2015 Zhang et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]White HD, Chew DP: Acute myocardial infarction. Lancet 2008, 372(9638):570-584.
• [2]Yusuf S, Reddy S, Ounpuu S, Anand S: Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001, 104(22):2746-2753.
• [3]Sodha NR, Clements RT, Feng J, Liu Y, Bianchi C, Horvath EM, et al.: Hydrogen sulfide therapy attenuates the inflammatory response in a porcine model of myocardial ischemia/reperfusion injury. J Thorac Cardiovasc Surg 2009, 138(4):977-984.
• [4]Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, et al.: Cardiovascular disease and risk factors in Asia: a selected review. Circulation 2008, 118(25):2702-2709.
• [5]Moran A, Gu D, Zhao D, Coxson P, Wang YC, Chen CS, et al.: Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china. Circ Cardiovasc Qual Outcomes 2010, 3(3):243-252.
• [6]Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, et al.: Rapid health transition in china, 1990–2010: findings from the global burden of disease study 2010. Lancet 2013, 381(9882):1987-2015.
• [7]Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, Galvani M, et al.: It's time for a change to a troponin standard. Circulation 2000, 102(11):1216-1220.
• [8]Zamore PD, Haley B: Ribo-genome: the big world of small RNAs. Science 2005, 309(5740):1519-1524.
• [9]Mattick JS, Makunin IV: Non-coding RNA. Hum Mol Genet 2006, 15 Sepc No 1:R17-29.
• [10]Plasterk RH: Micro RNAs in animal development. Cell 2006, 124(5):877-881.
• [11]Small EM, Olson EN: Prevasive roles of microRNAs in cardiovascular biology. Nature 2011, 469(7330):336-342.
• [12]Meltzer PS: Cancer genomics: small RNAs with big impacts. Nature 2005, 435(7043):745-746.
• [13]Sayed D, Abdellatif M: MicroRNAs in development and disease. Physiol Rev 2011, 91(3):827-887.
• [14]van Rooij E, Liu N, Olson EN: MicroRNAs flex their muscles. Trends Genet 2008, 24(4):159-166.
• [15]Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T: Identification of tissue-specific microRNAs from mouse. Curr Biol 2002, 12(9):735-739.
• [16]van Empel VP, De Windt LJ, da Costa Martins PA: Circulating miRNAs: reflecting or affecting cardiovascular disease? Curr Hypertens Rep 2012, 14(6):498-509.
• [17]Kloosterman WP, Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell 2006, 11(4):441-450.
• [18]Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al.: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105(30):10513-10518.
• [19]Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, et al.: Serum microRNAs are promising novel biomarkers. PLoS One 2008., 3(9) Article ID e3148
• [20]Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al.: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18(10):997-1006.
• [21]Häntzsch M, Tolios A, Beutner F, Nagel D, Thiery J, Teupser D, et al.: Comparison of whole blood RNA preservation tubes and novel generation RNA extraction kits for analysis of mRNA and MiRNA profiles. PLoS One 2014., 9(12) Article ID e113298
• [22]Zhou H, He XY, Zhuang SW, Wang J, Lai Y, Qi WG, et al.: Clinical and procedural predictors of no-reflow in patients with acute myocardial infarction after primary percutaneous coronary intervention. World J Emerg Med 2014, 5(2):96-102.
• [23]Long G, Wang F, Duan Q, Chen F, Yang S, Gong W, et al.: Human circulating microRNA-1 and microRNA-126 as potential novel indicators for acute myocardial infarction. Int J Biol Sci 2012, 8(6):811-818.
• [24]Bostjancic E, Zidar N, Stajer D, Glavac D: MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology 2010, 115(3):163-169.
• [25]Xiao J, Shen B, Li J, Lv D, Zhao Y, Wang F, et al.: Serum microRNA-499 and microRNA-208a as biomarkers of acute myocardial infarction. Int J Clin Exp Med 2014, 7(1):136-141.
• [26]He F, Lv P, Zhao X, Wang X, Ma X, Meng W, et al.: Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction. Mol Cell Biochem 2014, 394(1–2):137-144.
• [27]Chen D, Goswami CP, Burnett RM, Anjanappa M, Bhat-Nakshatri P, Muller W, et al.: Cancer affects microRNA expression, release, and function in cardiac and skeletal muscle. Cancer Res 2014, 74(16):4270-4281.
• [28]Hsu A, Chen SJ, Chang YS, Chen HC, Chu PH: Systemic approach to identify serum microRNAs as potential biomarkers for acute myocardial infarction. Biomed Res Int 2014, 2014:418628.
• [29]Zheng HW, Wang YL, Lin JX, Li N, Zhao XQ, Liu GF, et al.: Circulating MicroRNAs as potential risk biomarkers for hematoma enlargement after intracerebral hemorrhage. CNS Neurosci Ther 2012, 18(12):1003-1011.
• [30]Olivieri F, Antonicelli R, Capogrossi MC, Procopio AD: Circulating microRNAs (miRs) for diagnosing acute myocardial infarction: an exciting challenge. Int J Cardiol 2013, 167(6):3028-3029.
• [31]Recchioni R, Marcheselli F, Olivieri F, Ricci S, Procopio AD, Antonicelli R: Conventional and novel diagnostic biomarkers of acute myocardial infarction: a promising role for circulating microRNAs. Biomarkers 2013, 18(7):547-558.
• [32]Sayed AS, Xia K, Yang TL, Peng J: Circulating microRNAs: a potential role in diagnosis and prognosis of acute myocardial infarction. Dis Markers 2013, 35(5):561-566.
• [33]Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M, et al.: Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet 2011, 4(4):446-454.
• [34]Small EM, O'Rourke JR, Moresi V, Sutherland LB, McAnally J, Gerard RD, et al.: Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486. Proc Natl Acad Sci U S A 2010, 107(9):4218-4223.
• [35]Alexander MS, Casar JC, Motohashi N, Myers JA, Eisenberg I, Gonzalez RT, et al.: Regulation of DMD pathology by an ankyrin-encoded miRNA. Skelet Muscle 2011, 1:27. BioMed Central Full Text
• [36]Devaux Y, Vausort M, McCann GP, Zangrando J, Kelly D, Razvi N, et al.: MicroRNA-150: a novel marker of left ventricular remodeling after acute myocardial infarction. Circ Cardiovasc Genet 2013, 6(3):290-298.
• [37]Devaux Y, Vausort M, McCann GP, Kelly D, Collignon O, Ng LL, et al.: A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction. PLoS One 2013., 8(8) Article ID e70644
• [38]Li X, Kong M, Jiang D, Qian J, Duan Q, Dong A: MicroRNA-150 aggravates H2O2-induced cardiac myocyte injury by down-regulating c-myb gene. Acta Biochim Biophys Sin (Shanghai) 2013, 45(9):734-741.
• [39]Rhodes CJ, Wharton J, Boon RA, Roexe T, Tsang H, Wojciak-Stothard B, et al.: Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013, 187(3):294-302.
• [40]Zeller T, Keller T, Ojeda F, Reichlin T, Twerenbold R, Tzikas S, et al.: Assessment of microRNAs in patients with unstable angina pectoris. Eur Heart J 2014, 35(31):2106-2114.
• [41]Tang Y, Wang Y, Park KM, Hu Q, Teoh JP, Broskova Z, Ranganathan P, Jayakumar C, Li J, Su H, Tang Y, Ramesh G, Kim IM: MicroRNA-150 protects the mouse heart from ischemic injury by regulating cell death. Cardiovasc Res 2015 (in press).